Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses.

L Belbasis, C A Köhler, N Stefanis, B Stubbs, J van Os, E Vieta, M V Seeman, C Arango, A F Carvalho, E Evangelou

Journal: Acta psychiatrica Scandinavica 2019;137(2):88-97

PMID: 29288491

Abstract

OBJECTIVE

This study aimed to systematically appraise the meta-analyses of observational studies on risk factors and peripheral biomarkers for schizophrenia spectrum disorders.

METHODS

We conducted an umbrella review to capture all meta-analyses and Mendelian randomization studies that examined associations between non-genetic risk factors and schizophrenia spectrum disorders. For each eligible meta-analysis, we estimated the summary effect size estimate, its 95% confidence and prediction intervals and the I metric. Additionally, evidence for small-study effects and excess significance bias was assessed.

RESULTS

Overall, we found 41 eligible papers including 98 associations. Sixty-two associations had a nominally significant (P-value <0.05) effect. Seventy-two of the associations exhibited large or very large between-study heterogeneity, while 13 associations had evidence for small-study effects. Excess significance bias was found in 18 associations. Only five factors (childhood adversities, cannabis use, history of obstetric complications, stressful events during adulthood, and serum folate level) showed robust evidence.

CONCLUSION

Despite identifying 98 associations, there is only robust evidence to suggest that cannabis use, exposure to stressful events during childhood and adulthood, history of obstetric complications, and low serum folate level confer a higher risk for developing schizophrenia spectrum disorders. The evidence on peripheral biomarkers for schizophrenia spectrum disorders remains limited.

© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Address: Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.; Translational Psychiatry Research Group, Department of Clinical Medicine, Federal University of Ceará Medical School, Fortaleza, Brazil.; Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.; Department of Physiotherapy, South London and Maudsley NHS Foundation Trust, London, UK.; Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Centre Utrecht, Utrecht, The Netherlands.; Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.; Bipolar Disorder Unit, Institute of Neuroscience, University of Barcelona, IDIBAPS and CIBERSAM, Barcelona, Spain.; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.; Department of Child and Adolescent Psychiatry, University Hospital Gregorio Marañón, Complutense University of Madrid Medical School, CIBERSAM, Madrid, Spain.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Centre for Addiction & Mental Health (CAMH), Toronto, ON, Canada.; Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.